MIA Versus Wholesale Dealer's Licence: Which UK Authorisation Do You Need?

UK Manufacturer's / Importer's Authorisation (MIA) — MHRA authorisation required for covered manufacture or importation of medicinal products. Distinguishing an MIA from a Wholesale Dealer's Licence (WDL) and other UK permissions is crucial for operators designing compliant supply chains.

Both the MIA and WDL are regulatory licences relating to medicines, but they target different activities and legal responsibilities. The MIA focuses on quality systems associated with the manufacture or importation of medicinal products. The WDL governs the wholesale distribution of medicines (sale or supply to healthcare professionals, pharmacies, hospitals and other entities) and sets requirements for storage, record-keeping, and distribution controls. Some organisations need one licence, some both, depending on the activities performed at the site.

Primary Differences

• Scope: MIA: manufacture and importation; WDL: wholesale distribution (including holding stock for resale).
• Core Focus: MIA: GMP and product quality systems; WDL: GDP (Good Distribution Practice), traceability and distribution controls.
• Typical Holders: MIA: manufacturers, CMOs, importers doing quality-affecting activities; WDL: wholesalers, distributors, logistics providers handling saleable stock.

When Operators Need Both

Many sites perform both manufacturing/import and wholesale functions. For example, a site that imports medicinal products, then stores and resells them to hospitals, may require both an MIA (to lawfully import and release product) and a WDL (to distribute). When both licences apply, responsibilities must be separated operationally and in documentation so that audits and regulatory oversight can distinguish manufacturing/import controls from distribution controls.

How Responsibilities Differ In Practice

MIA holders ensure product quality by enforcing GMP, running quality control testing, and maintaining release records. WDL holders prioritize maintaining the supply chain: preventing counterfeit infiltration, ensuring proper storage conditions through transport and depots, and documenting chain of custody. For cold-chain medicines, both licences emphasize temperature control, but the MIA’s concern is batch integrity and release; the WDL’s concern is preservation during distribution.

Practical Decision Matrix

• If You Repack Or Relabel For Sale: You likely need an MIA (manufacturing) and a WDL (distribution of saleable stock).
• If You Only Store And Dispatch On Behalf Of A Manufacturer: You may only need a WDL unless you undertake quality-release actions or manipulations that amount to manufacture.
• If You Import For Further Manufacture In The UK: An MIA is required for import and manufacturing steps; a WDL is not required if no wholesale distribution occurs.

Coordination And Contracts

Clear contractual arrangements and quality agreements eliminate ambiguity over which party is responsible for release, recalls, deviations and complaints. When separate legal entities hold MIA and WDL, both must permit inspections by MHRA and share information promptly during incidents. Formal SOPs should set out handover points—when responsibility for product moves from the MIA holder to the WDL holder and vice versa.

Example

A UK-based repackager imports bulk packed tablets and repackages them into branded consumer packs for national distribution. The company holds an MIA for import and repackaging activities and also holds a WDL to distribute finished packs to pharmacies. This dual-licensing model reflects the manufacturing and distribution stages performed on site.

Checklist To Determine Licensing Needs

• Activity Map: List every physical and quality-affecting step you perform on the product.
• Decision Points: Identify who makes the final batch-release or supply decisions.
• Legal Entity Review: Confirm which company is legally responsible at each stage.
• Documentation: Prepare SOPs and quality agreements reflecting the licensing model.

In short, the UK Manufacturer's / Importer's Authorisation (MIA) and the Wholesale Dealer's Licence address different parts of the medicines lifecycle—manufacture/import versus wholesale distribution—and operators must map activities, decide who legally holds each licence and document responsibilities to remain compliant with MHRA expectations.